Bulk Saw Palmetto Extract Supplier — Fatty Acid & Sterol Standardized 10%, 25% & 45%, B2B Wholesale
Valeherb supplies saw palmetto extract bulk wholesale, standardized to fatty acids and sterols at 10%, 25%, and 45%, from the berries of Serenoa repens (W. Bartram) Small — the American dwarf palm native to the southeastern United States. Commercial saw palmetto extract is defined by its lipidosterolic profile: a combination of free fatty acids (principally lauric, oleic, myristic, and linoleic acid) and phytosterols (principally β-sitosterol) obtained from the ripe berry. This compositional profile — not a single active molecule — is what the industry, including the US Pharmacopeia monograph, uses to standardize and grade this ingredient.[4]
On this page: available grades, why fatty acid/sterol standardization matters, research background, formulation applications, sourcing criteria, and regulatory guidance.
Available Grades
| Grade | Fatty Acids & Sterols | Typical Application |
|---|---|---|
| Standard | 10% | Full-spectrum positioning; functional food and beverage fortification |
| Mid-Potency | 25% | Mainstream capsule and tablet formulations |
| High-Potency | 45% | Concentrated formulations; compact dosing formats |
The US Pharmacopeia monograph for Serenoa extract specifies a total fatty acid content of 70–95% for the pharmaceutical-grade liposterolic extract used in most published clinical research — Valeherb’s grades allow formulators to select a concentration matched to their specific product format and target dose. Custom extraction solvent (ethanol or supercritical CO₂) available on request. MOQ, lead time, and current pricing available on inquiry.
Why Fatty Acid and Sterol Standardization — Not a Single “Active”
Unlike single-compound botanical actives, saw palmetto’s research base is built around a defined mixture rather than one isolated molecule. Both the free fatty acids and the phytosterol fraction contribute to the extract’s studied activity, and neither alone reproduces the full compositional profile used in most published research. This is why “saw palmetto extract” specified only by milligram weight (e.g., “320 mg”) is a much less precise specification than one defined by fatty acid and sterol percentage — two products at the same milligram weight can differ substantially in actual lipidosterolic content depending on raw berry quality and extraction method. For a full breakdown of what these percentages mean and how extraction method affects them, see Saw Palmetto Fatty Acid and Sterol Standardization: A Sourcing Guide.
Research Background
Provided as scientific context for formulators, not as claims for any Valeherb product.
Mechanism: 5-Alpha-Reductase Inhibition
The fatty acid and sterol fraction of saw palmetto extract has been studied for its ability to inhibit both isoforms of 5α-reductase, the enzyme that converts testosterone to dihydrotestosterone (DHT). Linoleic and oleic acid together account for roughly one-third of the lipidosterolic profile and have been identified as active inhibitors of 5α-reductase Type 1 in published in vitro research, with the fatty acid fraction also studied for direct interference with androgen receptor binding.[1],[3] A separate line of published research has also proposed anti-inflammatory activity (COX and 5-lipoxygenase inhibition) as a contributing mechanism, alongside the antiandrogenic pathway.[3] These are in vitro and mechanistic findings described here as research context. For a full review of the published mechanism evidence, see Saw Palmetto and 5-Alpha-Reductase: What the Research Evidence Shows.
Clinical Evidence — A Balanced View
Published clinical research on saw palmetto and lower urinary tract symptoms has produced mixed results depending on study design and formulation. The most recent Cochrane systematic review (2023 update, 27 randomized trials, 4,656 men) concluded that Serenoa repens alone “provides little to no benefits” for men with lower urinary tract symptoms due to benign prostatic enlargement compared with placebo, and noted that current clinical practice guidelines have shifted away from incorporating it into standard treatment protocols; the review noted more uncertainty remains regarding combination use with other phytotherapeutic agents.[5] Earlier individual trials using specific standardized liposterolic extract formulations had reported more favorable results, which is part of why the overall evidence picture remains debated in the literature. Separately, a 2020 systematic review of saw palmetto in androgenetic alopecia (hair loss) found the existing evidence generally favorable but limited by small sample sizes and short study durations across the available trials.[2] This is presented as a balanced summary of the current published evidence, not as a claim for any Valeherb product.
Formulation Applications
- Men’s health supplement capsules and softgels: 25% or 45% grade at typical inclusion levels matching published research formulations; commonly paired with pumpkin seed oil, nettle root extract, or pygeum in combination formulas
- Hair and scalp care formulations: Oral capsule or topical formats leveraging the same 5-alpha-reductase research background; 45% grade for concentrated positioning
- Full-spectrum wellness blends: 10% grade for broader functional food and beverage fortification where cost efficiency matters
- Combination formulas: Frequently formulated alongside other botanical extracts (pygeum, nettle root, pumpkin seed) targeting complementary mechanisms
Sourcing Criteria
| Criterion | What to Require |
|---|---|
| Species Confirmation | Serenoa repens (W. Bartram) Small berry confirmed on COA — the sole commercial source species |
| Fatty Acid & Sterol Content | Total fatty acid and sterol content verified per batch — not milligram weight alone, which does not confirm actual lipidosterolic concentration |
| Extraction Method | Confirm ethanol vs supercritical CO₂ extraction — both are established methods, but affect residual solvent profile and downstream regulatory documentation differently |
| Third-Party COA | Fatty acid/sterol content, heavy metals (USP <232>), pesticide residues, microbial limits (USP <2021>), moisture — per production batch from accredited laboratory |
Regulatory Guidance
- US (DSHEA): Structure/function claims regarding urinary comfort or general men’s wellness are supportable with published research — self-substantiation and FDA disclaimer required. Disease treatment claims (including for BPH) require drug-level approval and are not supported by current DSHEA positioning, particularly given the most recent Cochrane review’s conclusions. FDA-registered facility (21 CFR Part 111)
- Pharmacopeial reference: The US Pharmacopeia (USP) maintains a monograph for Serenoa extract specifying fatty acid and sterol content ranges — formulators referencing USP compliance should confirm current monograph requirements for their specific grade
- EU: Serenoa repens fruit extract has traditional herbal medicinal product registration in some EU member states for urinary symptoms; confirm current food supplement vs. traditional herbal medicinal product classification for your specific target market
- General: Given the documented PSA interference and the mixed clinical evidence base for BPH specifically, Valeherb recommends conservative, research-grounded claim positioning and independent regulatory review before finalizing any finished-product marketing
